Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 203pembrolizumab 167Pemetrexed 143Cisplatin 125durvalumab 75Paclitaxel 75osimertinib 70Nivolumab 68Docetaxel 66Specimen Handling 64atezolizumab 62Magnetic Resonance Spectroscopy 54Etoposide 47Gemcitabine 45Radiotherapy 42Radiosurgery 39130-nm albumin-bound paclitaxel 35Drug Therapy 32Bevacizumab 29Cetuximab 28Ipilimumab 27cemiplimab 25Taxes 24tislelizumab 21Platinum 21Immunoglobulin G 21amivantamab 19Radiation 19Disulfides 19Biopsy 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paroxetine × Thoracic × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡